Ludwig-Maximilian-Universität, Klinikum Großhadern
Welcome,         Profile    Billing    Logout  
 5 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Belka, Claus
RADIANCE, NCT04230759 / 2018-003005-25: Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group

Active, not recruiting
2
180
Europe
Chemotherapy, all brands of 5-fluorouracil (5-FU) are allowed, all brands of Mitomycin C (MMC) are allowed, Radiation, Durvalumab, PD-L1 inhibitor
Goethe University, German Cancer Aid, AstraZeneca
Anal Cancer, Anal Carcinoma, Anal Cancer Stage III, Anal Cancer Stage II
12/26
03/27
INDIRA-MISO, NCT03865277: Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging

Not yet recruiting
2
276
Europe
dose-escalated radiochemotherapy, dose-escalated radiochemotherapy with carbon ion boost, standard radiochemotherapy
Technische Universität Dresden
Head and Neck Squamous Cell Carcinoma
09/25
09/27
X-SMILE, NCT06834152: Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer

Recruiting
N/A
30
Europe
University of Zurich
Localized Prostate Carcinoma, Prostate Cancer (Adenocarcinoma), Prostate Hyperplasia, Lower Urinary Track Symptoms
09/26
06/31
DELPHI, NCT03396718: De-escalation of Adjuvant Radio (chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas

Recruiting
N/A
304
Europe
De-escalation radio(chemo)therapy - Level 1, De-escalation radio(chemo)therapy - Level 2, Standard radio(chemotherapy)
Technische Universität Dresden, German Cancer Research Center, National Center for Tumor Diseases (NCT) Dresden, National Center for Tumor Diseases, Heidelberg, Radiation Oncology Working Group of the German Cancer Society
Head-and-neck Squamous Cell Carcinoma
11/29
11/32
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Belka, Claus
RADIANCE, NCT04230759 / 2018-003005-25: Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group

Active, not recruiting
2
180
Europe
Chemotherapy, all brands of 5-fluorouracil (5-FU) are allowed, all brands of Mitomycin C (MMC) are allowed, Radiation, Durvalumab, PD-L1 inhibitor
Goethe University, German Cancer Aid, AstraZeneca
Anal Cancer, Anal Carcinoma, Anal Cancer Stage III, Anal Cancer Stage II
12/26
03/27
INDIRA-MISO, NCT03865277: Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging

Not yet recruiting
2
276
Europe
dose-escalated radiochemotherapy, dose-escalated radiochemotherapy with carbon ion boost, standard radiochemotherapy
Technische Universität Dresden
Head and Neck Squamous Cell Carcinoma
09/25
09/27
X-SMILE, NCT06834152: Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer

Recruiting
N/A
30
Europe
University of Zurich
Localized Prostate Carcinoma, Prostate Cancer (Adenocarcinoma), Prostate Hyperplasia, Lower Urinary Track Symptoms
09/26
06/31
DELPHI, NCT03396718: De-escalation of Adjuvant Radio (chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas

Recruiting
N/A
304
Europe
De-escalation radio(chemo)therapy - Level 1, De-escalation radio(chemo)therapy - Level 2, Standard radio(chemotherapy)
Technische Universität Dresden, German Cancer Research Center, National Center for Tumor Diseases (NCT) Dresden, National Center for Tumor Diseases, Heidelberg, Radiation Oncology Working Group of the German Cancer Society
Head-and-neck Squamous Cell Carcinoma
11/29
11/32

Download Options